Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMP761 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single ascending dose IMP761 Part A | EXPERIMENTAL | Randomized in 3:2 (IMP761:placebo) Cohort 1: 5 subjects |
| Single ascending dose Placebo Part A | PLACEBO_COMPARATOR | Randomized in 3:2 (IMP761:placebo) Cohort 1: 5 subjects |
| Single ascending dose IMP761 Part B KLH challenge | EXPERIMENTAL | Randomized in 4:1 (IMP761:placebo). KLH immunization followed by IMP761 on Day 1 and dermal rechallenge on day 2 (Cohorts 2-3) or on days 2, 9 and 23 (Cohorts 4-8) Cohort 2: 5 subjects; Cohort 3: 5 subjects; Cohort 4: 10 subjects; Cohort 5: 10 subjects; Cohort 6: 10 subjects; Cohort 7: 10 subjects; Cohort 8: 10 subjects |
| Single ascending dose Placebo Part B KLH challenge | PLACEBO_COMPARATOR | Randomized in 4:1 (IMP761:placebo). KLH immunization followed by placebo on Day 1 and dermal rechallenge on day 2 (Cohorts 2-3) or on days 2, 9 and 23 (Cohorts 4-8) Cohort 2: 5 subjects; Cohort 3: 5 subjects; Cohort 4: 10 subjects; Cohort 5: 10 subjects; Cohort 6: 10 subjects; Cohort 7: 10 subjects; Cohort 8: 10 subjects |
| Multiple ascending dose IMP761 Part C | EXPERIMENTAL | Randomized 5:2 (IMP761:placebo) every 28 days, 3 times. MAD Cohort 1: 7 subjects; MAD Cohort 2: 7 subjects |
| Multiple dose placebo Part C | PLACEBO_COMPARATOR | Randomized 5:2 (IMP761:placebo) every 28 days, 3 times. MAD Cohort 1: 7 subjects; MAD Cohort 2: 7 subjects |
| Name | Type | Description |
|---|---|---|
| IMP761 | DRUG | intravenous |
| Placebo | DRUG | intravenous |
| keyhole limpet haemocyanin (KLH) | OTHER | intramuscular immunization and intradermal challenge |
Inclusion Criteria: 1. Signed informed consent and willing and able to comply with the study protocol; 2. Healthy men or women, 18 to 55 years of age (inclusive) at screening. The health status is verified by absence of evidence of any clinically significant active or uncontrolled chronic disease f...
IMP761 is an investigational immunosuppressive antibody being studied in healthy volunteers. It is currently in a Phase 1 first-in-human clinical trial to evaluate its safety. The drug is being developed by Immutep Limited as a small molecule, though it is described as an antibody in the trial title.
IMP761 targets LAG-3, a protein involved in immune regulation. By targeting LAG-3, the drug is designed to have an immunosuppressive effect, which may have potential applications in autoimmune diseases or other conditions where dampening the immune response is desirable. However, its specific therapeutic indications are still under investigation.
IMP761 is being developed by Immutep Limited, a biopharmaceutical company listed on the stock exchange under the ticker IMMP. The company is conducting a Phase 1 clinical trial to assess the safety of this investigational drug in healthy volunteers.
IMP761 is in Phase 1 clinical development. It is currently being evaluated in a first-in-human study that is recruiting participants. The drug is investigational and has not been approved by regulatory authorities. The trial is designed to assess its safety in healthy volunteers.
IMP761 is being studied in one active clinical trial, NCT06637865, titled 'A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers.' This Phase 1 trial is recruiting 79 participants in the Netherlands and is randomized, double-blind, and placebo-controlled.
Yes, IMP761 is described as an immunosuppressive antibody in its clinical trial title. It is being developed to suppress the immune system by targeting LAG-3. The drug is currently in Phase 1 testing to evaluate its safety in healthy volunteers, and its mechanism involves modulating immune responses.